コンテンツへスキップ
Merck
  • Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.

Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2013-03-29)
Alicia Anderson, Henk Bijlmer, Pierre-Edouard Fournier, Stephen Graves, Joshua Hartzell, Gilbert J Kersh, Gijs Limonard, Thomas J Marrie, Robert F Massung, Jennifer H McQuiston, William L Nicholson, Christopher D Paddock, Daniel J Sexton
要旨

Q fever, a zoonotic disease caused by the bacterium Coxiella burnetii, can cause acute or chronic illness in humans. Transmission occurs primarily through inhalation of aerosols from contaminated soil or animal waste. No licensed vaccine is available in the United States. Because many human infections result in nonspecific or benign constitutional symptoms, establishing a diagnosis of Q fever often is challenging for clinicians. This report provides the first national recommendations issued by CDC for Q fever recognition, clinical and laboratory diagnosis, treatment, management, and reporting for health-care personnel and public health professionals. The guidelines address treatment of acute and chronic phases of Q fever illness in children, adults, and pregnant women, as well as management of occupational exposures. These recommendations will be reviewed approximately every 5 years and updated to include new published evidence.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ドキシサイクリン ハイクレート
Sigma-Aldrich
ドキシサイクリン塩酸塩、調製済み溶液
Sigma-Aldrich
ドキシサイクリン 一水和物
Supelco
ドキシサイクリン ハイクレート, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ドキシサイクリン ハイクレート, VETRANAL®, analytical standard